Document is current
Any future updates will be listed below
-
Authors
Lovley, Andrew https://orcid.org/0000-0001-9118-0673
Hsu, Kristen https://orcid.org/0000-0003-2106-3652
LaGasse, Kaitlin https://orcid.org/0000-0001-9772-5822
Lousada, Isabelle https://orcid.org/0000-0002-3506-0359
McCausland, Kristen L. https://orcid.org/0000-0003-4727-1046
Carty, Michelle K. https://orcid.org/0000-0003-2450-7693
Rebello, Sabrina https://orcid.org/0000-0002-0201-4030
Bjorner, Jakob B. https://orcid.org/0000-0001-7033-8224
-
Funding
Funding for this research was provided by:
Amyloidosis Research Consortium (Amyloidosis Research Consortium)
Ionis Pharmaceuticals (Ionis Pharmaceuticals)
Alnylam Pharmaceuticals (Alnylam Pharmaceuticals)
Pfizer (Pfizer)
Prothena (Prothena)
- License Information
-
More Information
Article History
Received: 8 December 2024
Accepted: 14 April 2025
First Online: 29 April 2025
Declarations
:
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by an independent Institutional Review Board (Western Institutional Review Board-Copernicus Group [WCG], #20221357).
: Not applicable—no individual level data included in publication.
: Informed consent was obtained from all individual participants included in the study.
: AL, KL, KLM, MKC, and JBB are employees of IQVIA QualityMetric, and received funding as describe above to conduct this research. KH, IL, and SR are employees of the Amyloidosis Research Consortium and received funding as described above to conduct this research.
